PRPO stock forecast
Our latest prediction for Precipio, Inc.'s stock price was made on the Dec. 2, 2019 when the stock price was at 2.09$.
In the short term (2weeks), PRPO's stock price should underperform the market by -4.67%. During that period the price should oscillate between -13.00% and +14.76%.
In the medium term (3months), PRPO's stock price should underperform the market by -25.28%. During that period the price should oscillate between -48.08% and +34.00%.Get email alerts
Create a solid portfolio with PRPO
About Precipio, Inc.
Precipio, Inc. is a cancer diagnostics company, which engages in the development and provision of a platform designed to eradicate the problem of misdiagnosis. Its products include MX-ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HRM kits and ICP liquid biopsy testing. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
At the moment the company generates 3M USD in revenues.
On its last earning announcement, the company reported a loss of -5.35$ per share.
The book value per share is 0.53$
Three months stock forecastDec. 2, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|